Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.38+0.10 (+1.37%)
Close on Nov 18, 2026Market cap $1.92BP/E –Yield –
Maravai LifeSciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Maravai LifeSciences's operating income for the twelve months ending Jun 30, 2026 was -$117.07M. For fiscal 2025 it was -$215.27M. The highest annual figure on record is $574.22M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$215.27M | – |
| FY2024 | Dec 31, 2024 | -$235.62M | – |
| FY2023 | Dec 31, 2023 | -$31.65M | -105.5% |
| FY2022 | Dec 31, 2022 | $574.22M | +3.5% |
| FY2021 | Dec 31, 2021 | $554.65M | +362.6% |
| FY2020 | Dec 31, 2020 | $119.90M | +399.8% |
| FY2019 | Dec 31, 2019 | $23.99M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.09M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$58.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$41.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$66.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$49.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$165.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.44M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.86M | -844.6% |
| Q4 FY2023 | Dec 31, 2023 | -$7.15M | -106.5% |
| Q3 FY2023 | Sep 30, 2023 | -$15.42M | -113.2% |
| Q2 FY2023 | Jun 30, 2023 | -$11.61M | -106.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.53M | -98.5% |
| Q4 FY2022 | Dec 31, 2022 | $109.25M | -29.3% |
| Q3 FY2022 | Sep 30, 2022 | $116.90M | -24.8% |
| Q2 FY2022 | Jun 30, 2022 | $180.70M | +17.7% |
| Q1 FY2022 | Mar 31, 2022 | $167.37M | +83.5% |
| Q4 FY2021 | Dec 31, 2021 | $154.54M | +394.6% |
| Q3 FY2021 | Sep 30, 2021 | $155.38M | +239.8% |
| Q2 FY2021 | Jun 30, 2021 | $153.54M | +1790.8% |
| Q1 FY2021 | Mar 31, 2021 | $91.19M | +161.9% |
| Q4 FY2020 | Dec 31, 2020 | $31.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $45.72M | – |
| Q2 FY2020 | Jun 30, 2020 | $8.12M | – |
| Q1 FY2020 | Mar 31, 2020 | $34.82M | – |
See a number that looks wrong?